Matrix metalloproteinases activity during the evolution of hypoxic-ischemic brain damage in the immature rat. The effect of 1-methylnicotinamide (MNA)

Journal of Physiology and Pharmacology

Volumn 59, Issue 3, 2008, Pages 441-455

  Dragun, P ^a   Makarewicz, D ^a   Wojcik L ^c   Ziemka Nalecz M ^a   Slomka M ^a   Zalewska, Teresa ^a,b  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

^c NONE

Author keywords

Hypoxia ischemia; Immature rat brain; Matrix metalloproteinase; MMP 2; MMP 9

Indexed keywords

1 METHYLNICOTINAMIDE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE; N(1) METHYLNICOTINAMIDE; N(1)-METHYLNICOTINAMIDE; NICOTINAMIDE; NICOTINIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN DAMAGE; BRAIN DEVELOPMENT; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FOREBRAIN; NERVE CELL NECROSIS; NEUROPROTECTION; NEWBORN; NONHUMAN; PERINATAL ASPHYXIA; RAT; SINGLE DRUG DOSE; AGING; ANIMAL; BRAIN; BRAIN LEVEL; DRUG EFFECT; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PATHOLOGY; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; WISTAR RAT;

AGING; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; BRAIN CHEMISTRY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HYPOXIA-ISCHEMIA, BRAIN; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NIACINAMIDE; NICOTINIC AGONISTS; RATS; RATS, WISTAR;

EID: 53649104003     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005; 50: 329-339.
2. Gasche Y, Soccal PM, Kanemitsu M, Copin J-C. Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. Front in Biosci 2006; 11: 1289-1301.
3. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 1998; 18: 1163-1172.
4. Rosenberg GA, Estrada EY, Dencoff J.E. Matrix metalloproteinases and TIMPs are associated with blood-brain-barrier opening after reperfusion in rat brain. Stroke 1998; 29: 2189-2195.
5. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone F.C. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats. Inhibition of matrix metalloproteinase-9 reduced infarct size. Stroke 1998; 29: 1020-1030.
6. Gasche Y, Fujimura M, Morita-Fujimura Y, et al. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: A possible role in blood-brain barrier dysfunction, J Cereb Blood Flow Metab 1999; 19: 1020-1028.
7. Rivera S, Ogier C, Jourquin J, et al. Gelatinase B and TIMP-1 are regulated in a cell- and time-dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia. Europ J Neurosc 2002; 15: 19-32.
8. Zalewska T, Ziemka-Nalȩcz M, Sarnowska A, Domańska-Janik K. Involvement of MMPs in delayed neuronal death after global ischemia. Acta Neurobiol Exp 2002; 62: 53-61.
9. Sironi L, Calvio AM, Bellosta S, et al. Endogenous proteolytic activity in a rat model of spontaneous cerebral stroke. Brain Res 2003; 974: 184-192.
10. Copin JC, Goodyear MC, Gidday JM, Shah AR, Gascon E, Dayer A et al. Role of matrix metalloproteinases in apoptosis after transient focal cerebral ischemia in rats and mice. Eur J Neurosci 2005; 22: 1597-1608
11. Hagberg B, Hagberg G. Dyskinetic and dystonic cerebral palsy and birth. Acta Pediatr 1992; 81: 93-94.
12. Milligan CE, Levitt P, Cunningham TJ. Brain macrophages and microglia respond differently to lesions of the developing and adult visual system. J Comp Neurol 1991; 314: 136-146.
13. Palmer C, Vanucci RC, Towfighi J. Reduction of perinatal hypoxic-ischemic brain damage with alopurinol. Pediatr Res 1990; 27: 332-336.
14. Lee CZ, Xu B, Hashimoto T, McCulloh CE, Yang GY, Young WL. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke 2004; 35: 1715-1719.
15. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC. Delayed minocycline inhibits ischemia-activated MMP 2 and 9 after experimental stroke. BMC Neuroscience 2006; 7: 1-7.
16. Rice JE, Vanucci RC, Brierley JB. The influence of immaturity on hypoxic-ischemic brain damage in the rat. Ann Neurol 1981; 9: 131-141.
17. Silverstain F, Buchanan K, Johnston MV. Pathogenesis of hypoxic-ischemic brain injury in a perinatal rodent model. Neurosci Lett 1984; 49: 271-277.
18. Towfighi J, Yager JY, Vanucci RC. Neuropathology of remote hypoxic-ischemic damage in the immature rat. Acta Neuropathol 1991; 81: 578-587.
19. Slomka M, Zieminska E, Makarewicz D, Lazarewicz L. Neuroprotective potential of nicotinamide and methylnicotinamide: an in vitro and in vivo study. FENS Forum Abstracts 2006; 3: A058.20
20. Zhang JW, Gottschall PE. Zymographic measurement of gelatinase activity in brain tissue after detergent extraction and affinity-support purification. J Neurosci Methods 1997; 76: 15-20.
21. Heo JH, Lucero J, Abymiya T, Koizol JA, Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999; 19: 624-633.
22. Vannucci SJ, Hagberg H. Hypoxia-ischemia in the immature brain. J Exp Biol 2004; 207: 3149-3154.
23. Svedin P, Hagberg H, Sawman K, Zhu Ch, Mallard C. Matrix metalloproteinase-9 knock-out protects the immature brain after cerebral hypoxia-ischemia. J Neurosci 2007; 27: 1511-1518.
24. Asahi M, Sumii T, Fini ME, Itohara S, Lo EH. Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. NeuroReport 2001; 12: 3003-3007.
25. Muramatsu K, Fukuda A, Togari H, Wada Y, Nishino H. Vulnerability to cerebral hypoxic-ischemic insult in neonatal but not in adult rats is in parallel with disruption of the blood-brain barrier. Stroke 1997; 28: 2281-2289.
26. Hedtjarn M, Mallard C, Hagberg H. Inflammatory gene profiling in the developing mouse brain after hypoxia-ischemia. J Cereb Blood Flow Metab 2004; 24: 1333-1351
27. Gu Z, Cui J, Brown S, Friedman R, et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 2005; 25: 6401-6408.
28. Ziemka-Nalecz M, Zalewska T. Transient forebrain ischemia effects FAK-coupled signaling in gerbil hippocampus. Neurochem Intern 2007; 51: 405-411.
29. Opdenakker G, Van den Steen PE, Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001; 22: 571-579.
30. Schonbeck U, Mach F, Liby P. Generation of biologically active Il-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of Il-1-beta processing. J Immunol 1998; 161: 3340-3346.
31. Saren P, Welgus HG, Kovanen PT. TNF-alfa and Il-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 1996; 157: 4159-4165.
32. Hara H, Friedlander RM, Gagliardini V, et al. Inhibition of interleukin-1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA 1997; 94: 2007-2012.
33. Vecil GG, Larsen PH, Corley S M, et al. Interleukin 1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo. J Neurosci Res 2000; 61: 212-224.
34. Hagberg H, Gilland E, Bona E, et al. Enhanced expression of Il-1 and Il-6 messenger RNA and bioactive protein after hypoxia-ischemia in neonatal rats. Pediatric Res 1996; 40: 603-609
35. Zalewska T, Makarewicz D, Janik B, Ziemka-Nalecz M. Neonatal cerebral hypoxia-ischemia: involvement of FAK-dependent pathway. Int J Devl Neuroscience 2005; 23: 657-662.
36. Cramer SC, Chopp M. Recovery recapitulates ontogeny. Trends Neurosci 2000; 23: 265-271.
37. Szklarczyk A, Lapinska J, Rylski M, McKay RD, Kaczmarek L. Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J Neurosci 2002; 22: 920-930.
38. Zhao B-Q, Wang S, Kim H-Y, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006; 12: 441-445.
39. Larsen PH, Wells JE, Stallcup WB, Opdenakker G, Yong V.W. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci 2003; 23: 11127-11135.
40. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21: 1104-1117
41. Wetzel M, Rosenberg GA, Cunningham LA. Tissue inhibitor of metalloproteinase-3 and matrix metalloproteinase-3 regulate neuronal sensitivity to doxorubicin-induced apoptosis. Eur J Neurosci 2003;18: 1050-1060.
42. Yong VW. Metalloproteinases: mediators of pathology regeneration in the CNS. Nat Rev Neurosci 2005; 6: 931-944.
43. Xu L, Fagan SC, Waller JL, et al. Low dose intravenous minocycline is neuroprotectiver after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol 2004; 4:7
44. Zemke D, Majid A. The potential of minocycline for neuroprotection in human neurologic disease. Clin Neuropharmacol 2004; 27: 293-298.
45. Golub ML, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12: 12-26
46. Gebicki J, Sysa-Jedrzejowska A, Adamus J, Wozniacka A, Rybak M, Zielonka J. 1-methylnicotinamide: a potent anti-inflammatory agent of vitamin origin. Pol J Pharmacol 2003; 55: 109-112.
47. Bryniarski K, Biedron R, Jakubowski A, Chłopicki S, Marcinkiewicz J. Anti-inflammatory effect of 1-methylnicotinamide in contact hypersensitivity to oxazolone in mice; involvement of prostacyclin. Eur J Pharmacol 2008; 578: 332-338.
48. Hagberg H, Gilland E, Diemer NH, Andine P. Hypoxia-ischemia in the neonatal rat brain: histopathology after post-treatment with NMDA and non-NMDA receptor antagonists. Biol Neonate 1994; 66: 205-213.
49. Towfighi J, Housman C, Vanucci R.C, Heitjan D.F. Effect of unilateral perinatal hypoxicischemic brain damage on the gross development of opposite cerebral hemisphere. Biol Neonate 1994; 65: 108-118.